[1] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer Clin, 68 (2018) 394-424.
[2] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019, CA Cancer J Clin, 69 (2019) 7-34.
[3] M. Li, F. Liu, F. Zhang, W. Zhou, X. Jiang, Y. Yang, K. Qu, Y. Wang, Q. Ma, T. Wang, L. Bai, Z. Wang, X. Song, Y. Zhu, R. Yuan, Y. Gao, Y. Liu, Y. Jin, H. Li, S. Xiang, Y. Ye, Y. Zhang, L. Jiang, Y. Hu, Y. Hao, W. Lu, S. Chen, J. Gu, J. Zhou, W. Gong, Y. Zhang, X. Wang, X. Liu, C. Liu, H. Liu, Y. Liu, Y. Liu, Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis, Gut, 68 (2019) 1024-1033.
[4] S. Roychowdhury, A.M. Chinnaiyan, Translating cancer genomes and transcriptomes for precision oncology,CA Cancer J Clin, 66 (2016) 75-88.
[5] A. Citri, Y. Yarden, EGF-ERBB signalling: towards the systems level, Nat Rev Mol Cell Biol, 7 (2006) 505-516.
[6] S. Kumagai, S. Koyama, H. Nishikawa, Antitumour immunity regulated by aberrant ERBB family signalling, Nat Rev Cancer, 21 (2021) 181-197.
[7] Y. Yarden, M.X. Sliwkowski, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2 (2001) 127-137.
[8] K.B. Pahuja, T.T. Nguyen, B.S. Jaiswal, K. Prabhash, T.M. Thaker, K. Senger, S. Chaudhuri, N.M. Kljavin, A. Antony, S. Phalke, P. Kumar, M. Mravic, E.W. Stawiski, D. Vargas, S. Durinck, R. Gupta, A. Khanna-Gupta, S.E. Trabucco, E.S. Sokol, R.J. Hartmaier, A. Singh, A. Chougule, V. Trivedi, A. Dutt, V. Patil, A. Joshi, V. Noronha, J. Ziai, S.D. Banavali, V. Ramprasad, W.F. DeGrado, R. Bueno, N. Jura, S. Seshagiri, Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations, Cancer Cell, 34 (2018) 792-806 e795.
[9] B.T. Li, D.S. Ross, D.L. Aisner, J.E. Chaft, M. Hsu, S.L. Kako, M.G. Kris, M. Varella-Garcia, M.E. Arcila, HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers, J Thorac Oncol, 11 (2016) 414-419.
[10] L.F. Abrahao-Machado, C. Scapulatempo-Neto, HER2 testing in gastric cancer: An update, World JGastroenterol, 22 (2016) 4619-4625.
[11] L. Gianni, Is there room for another HER2-targeting drug?, Lancet Oncol, 19 (2018) 847-849.
[12] H. Greulich, B. Kaplan, P. Mertins, T.H. Chen, K.E. Tanaka, C.H. Yun, X. Zhang, S.H. Lee, J. Cho, L. Ambrogio, R. Liao, M. Imielinski, S. Banerji, A.H. Berger, M.S. Lawrence, J. Zhang, N.H. Pho, S.R. Walker, W. Winckler, G. Getz, D. Frank, W.C. Hahn, M.J. Eck, D.R. Mani, J.D. Jaffe, S.A. Carr, K.K. Wong, M. Meyerson, Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2, Proc Natl Acad Sci U S A, 109 (2012) 14476-14481.
[13] N. Kiavue, L. Cabel, S. Melaabi, G. Bataillon, C. Callens, F. Lerebours, J.Y. Pierga, F.C. Bidard, ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics, Oncogene, 39 (2020) 487-502.
[14] K. Fan, Z. Fan, H. Cheng, Q. Huang, C. Yang, K. Jin, G. Luo, X. Yu, C. Liu, Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer, Cancer Med, 8 (2019) 5903-5915.
[15] R.R. Narayan, J.M. Creasy, D.A. Goldman, M. Gonen, C. Kandoth, R. Kundra, D.B. Solit, G. Askan, D.S. Klimstra, O. Basturk, P.J. Allen, V.P. Balachandran, M.I. D'Angelica, R.P. DeMatteo, J.A. Drebin, T.P. Kingham, A.L. Simpson, G.K. Abou-Alfa, J.J. Harding, E.M. O'Reilly, J.M. Butte, R. Matsuyama, I. Endo, W.R. Jarnagin, Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations, Cancer, 125 (2019) 575-585.
[16] M. Li, Z. Zhang, X. Li, J. Ye, X. Wu, Z. Tan, C. Liu, B. Shen, X.A. Wang, W. Wu, D. Zhou, D. Zhang, T. Wang, B. Liu, K. Qu, Q. Ding, H. Weng, Q. Ding, J. Mu, Y. Shu, R. Bao, Y. Cao, P. Chen, T. Liu, L. Jiang, Y. Hu, P. Dong, J. Gu, W. Lu, W. Shi, J. Lu, W. Gong, Z. Tang, Y. Zhang, X. Wang, Y.E. Chin, X. Weng, H. Zhang, W. Tang, Y. Zheng, L. He, H. Wang, Y. Liu, Y. Liu, Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway, Nat Genet, 46 (2014) 872-876.
[17] A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, D.J. Leahy, M.A. Lemmon, M.X. Sliwkowski, C.W. Ward, S. Yokoyama, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors, Mol Cell, 12 (2003) 541-552.
[18] K. Roepstorff, L. Grovdal, M. Grandal, M. Lerdrup, B. van Deurs, Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer, Histochem Cell Biol, 129 (2008) 563-578.
[19] M. Ponz-Sarvise, V. Corbo, H. Tiriac, D.D. Engle, K.K. Frese, T.E. Oni, C.I. Hwang, D. Ohlund, I.I.C. Chio, L.A. Baker, D. Filippini, K. Wright, T.E. Bapiro, P. Huang, P. Smith, K.H. Yu, D.I. Jodrell, Y. Park, D.A. Tuveson, Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer, Clin Cancer Res, 25 (2019) 6742-6755.
[20] J. Zhou, T. Du, B. Li, Y. Rong, A. Verkhratsky, L. Peng, Crosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/Reperfusion, ASN Neuro, 7 (2015).
[21] P.J. Brennan, T. Kumagai, A. Berezov, R. Murali, M.I. Greene, HER2/neu: mechanisms of dimerization/oligomerization, Oncogene, 19 (2000) 6093-6101.
[22] R. Roskoski, Jr., The ErbB/HER family of protein-tyrosine kinases and cancer, Pharmacol Res, 79 (2014) 34-74.